Table 1.
Demographic characteristics and clinical parameter distribution of the study cohort (n = 540).
| Feature variable | Statistical description | Feature variable | Statistical description |
|---|---|---|---|
| Demographic characteristics | Metabolic diseases | ||
| Age [M, (IQR)] | 70.0 (59.0–77.0) | Type 2 diabetes (total cases) | 206 (38.1%) |
| Sex distribution | Diabetes duration | ||
| Male [n (%)] | 284 (52.6%) | <5 years [n (%)] | 46 (8.5%) |
| Female [n (%)] | 256 (47.4%) | 5–10 years [n (%)] | 29 (5.4%) |
| Vascular risk factors | >10 years [n (%)] | 79 (14.6%) | |
| Hypertension (total cases) | 331 (61.3%) | Unrecorded [n (%)] | 52 (9.6%) |
| Grade 1 [n (%)] | 38 (7.0%) | Laboratory Abnormalities | |
| Grade 2 [n (%)] | 91 (16.9%) | Elevated uric acid [n (%)] | 126 (23.3%) |
| Grade 3 [n (%)] | 196 (36.3%) | Cys-C abnormality [n (%)] | 109 (20.2%) |
| Other clinical parameters | Elevated creatinine [n (%)] | 105 (19.4%) | |
| Hyperlipidemia [n (%)] | 269 (49.8%) | β2-MG abnormality [n (%)] | 118 (21.9%) |
| Smoking history [n (%)] | 178 (33.0%) | Cardiovascular Diseases | |
| Alcohol consumption [n (%)] | 155 (28.7%) | Coronary heart disease [n (%)] | 96 (17.8%) |
M, Median; IQR, Interquartile range; Cys-C=Cystatin C; β2-MG = β2-microglobulin.